Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
David Thompson has served at Osteal Therapeutics President and CEO since August 2020. He brings over 20 years of experience in medical technology, most recently acting as Interim CEO of Gravitas Medical where he was a member of the Board of Directors since July 2018. Previously, David was based in London as Global Vice President of Strategic Development for Smith & Nephew where he oversaw company-wide strategic planning, business development and business intelligence. Prior to Smith & Nephew David held senior commercial leadership roles at Barrx Medical (Covidien) and Kyphon (Medtronic).
David received an MBA from the Haas School of Business at
UC Berkeley and a BA in International Relations from UCLA.